BrickBio, Inc.
Colby Souders has an extensive background in scientific research and development. In 2023, they joined BrickBio, Inc. as the Chief Scientific Officer. Prior to that, from 2021 to 2023, they worked as the Senior Director of R&D at Twist Bioscience. From 2018 to 2023, they held the position of Chief Scientific Officer at Abveris, where they were also the Chief Technology Officer from 2018 to 2019. Before that, from 2016 to 2018, they worked at Kanyos Bio, focusing on antibody discovery and engineering research. From 2012 to 2016, they were an R&D Scientist and Assistant Professor of Medicine at MassBiologics, where they developed biologics for various diseases. Their research career began in 2009 as a Research Graduate Student at Texas A&M Health Science Center, where they continued their cardiovascular and cancer research. Prior to that, from 2007 to 2012, they were a Research Graduate Student at the University of South Carolina, conducting cardiovascular and cancer research.
Colby Souders has an extensive education history. From 2003 to 2007, they attended Colby College, where they pursued a Bachelor of Arts degree. During this time, their majors were Biochemistry (Chemistry) and Neuroscience.
Following their undergraduate studies, from 2007 to 2012, Colby Souders enrolled at the University of South Carolina School of Medicine. During this period, they pursued a Ph.D. degree with a specialization in Biomedical Science, specifically in the field of Cell and Molecular Biology.
In 2009, Colby Souders also attended the Texas A&M University School of Medicine, where they pursued a Doctor of Philosophy (PhD) degree. Here, their field of study was Cell/Cellular and Molecular Biology.
Additionally, from 2009 to 2012, Colby Souders also attended the Texas A&M University Health Science Center, where they pursued another Ph.D. degree, this time in Biomedical Sciences, General.
Overall, Colby Souders' education history demonstrates a strong focus on biomedical sciences, with an emphasis on cell and molecular biology.
This person is not in any teams
BrickBio, Inc.
BrickBio is a developer of a bioconjugation platform intended for research of site-specific modification of proteins. The company's platform can optimize any conjugate with the selective modification of a number of distinct websites on a single protein through its prokaryotic and eukaryotic expression programs, thereby providing hospitalswith amino acid coupled therapeutics to improve protein characteristics.